Dr Jyoti Nangalia from the University of Cambridge Department of Haematology and Wellcome Sanger Institute has been awarded funding from the Rosetrees Trust for her project ‘Towards precision medicine: Integrating personalised prognostic predictions for patients with myeloid stem cell cancers into clinical care’.
Dr Nangalia together with co-investigators Professor Brian Huntly from the Department of Haematology and Dr Anna Godfrey from Cambridge University Hospitals will be building on their previous work and that of other researchers work that has led to the development of detailed prognostic tools for patients with acute myeloid leukaemia and myeloproliferative neoplasms. These studies have created a ‘knowledge bank’ based on patient data provided about different variables. These data have been used to build models to predict clinical end-points for patients. This project aims to improve these tools and to integrate them into routine patient management pathways with the aim of taking them forward to a clinical trial in the future.
The project has received matched funding from the Rosetrees Trust and the Stem Cells Interdisciplinary Research Centre which will enable the team to develop this research over the next two years with the ultimate aim of benefiting patients through personalised prognostics for these conditions.